Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | FABP1 | P07148 | 1/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10289575 | 0.85 | AURKA (0.48) | MEN1KMT2ACXCR4MAPK10GFER | |
| SCHEMBL9837237 | 0.82 | CYP1A2 (0.51) | MEN1KMT2ACXCR4MAPK10GFER | |
| SCHEMBL29590223 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPK10GFERALDH1A1 | |
| SCHEMBL3888498 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPK10GFERALDH1A1 | |
| SCHEMBL4926432 | 0.79 | ADRB2 (0.52) | ADRB2 | |
| SCHEMBL25201789 | 0.79 | CXCR4 (0.56) | MEN1KMT2ACXCR4MAPK10GFER | |
| SCHEMBL31390266 | 0.79 | MEN1 (0.59) | MEN1KMT2AMAPK10GFERALDH1A1 | |
| SCHEMBL5025381 | 0.79 | CXCR4 (0.82) | MEN1KMT2ACXCR4ADRB2FABP1 | |
| SCHEMBL29582475 | 0.78 | MEN1 (0.64) | MEN1KMT2AMAPK10GFERFABP1 | |
| SCHEMBL626575 | 0.78 | MEN1 (0.64) | MEN1KMT2AMAPK10GFERFABP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7125883-B1 | Integrin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2006-10-24 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1286673-B8 | LIGANDS OF INTEGRIN RECEPTORS | ABBOTT GMBH & CO KG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1286673-B1 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2005-05-25 | — | — | EP | disclosed |
| EP-1286673-A2 | LIGANDS OF INTEGRIN RECEPTORS | Basf Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| CN-1374960-A | novel integrin receptor antagonists | BASF AG (DE) | 2002-10-16 | — | — | CN | disclosed |
| EP-1202988-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-08 | — | — | EP | disclosed |
| EP-1171435-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001093840-A2 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001010847-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000061551-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | MEN1 4463/4885KMT2A 4698/4885CXCR4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.